Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by L...
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
- Conditions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 147
- Registration Number
- NCT01282762
- Locations
- 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 155
- Registration Number
- NCT01195246
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT01023230
- Locations
- 🇵🇱
Collegium Medicum Uniwersytet im. Mikołaja Kopernika, Bydgoszcz, Poland
🇵🇱NZOZ Centrum Badan Klinicznych, Wrocław, Poland
🇵🇱Wojewódzki Szpital Zakaźny, Warsaw, Poland
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
- Conditions
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 2452
- Registration Number
- NCT01005407
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
- Conditions
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 521
- Registration Number
- NCT00985426
- Locations
- 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT00823862
- Locations
- 🇵🇱
Wojewódzki Szpital Zakaźny, Warszawa, Poland
🇵🇱EMC Instytut Medyczny S.A. Szpital Specjalistyczny z Przychodnią "EuroMediCare", Wrocław, Poland
🇵🇱Klinika Chorób Zakaźnych i Hepatologii Collegium Medicum Uniwersytet Mikołaja Kopernika, Bydgoszcz, Poland
Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT00599001
- Locations
- 🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States
An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 271
- Registration Number
- NCT00537355
- Locations
- 🇨🇦
Allied Research International Inc., Mississauga, Ontario, Canada
🇨🇦Allergy & Asthma Research Centre, Ottawa, Ontario, Canada
🇨🇦Alpha Medical Research Inc., Mississauga, Ontario, Canada
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 207
- Registration Number
- NCT00511095
- Locations
- 🇺🇸
Beeghley Medical Park, Boardman, Ohio, United States
🇺🇸Family Healthcare Partners, Grove City, Pennsylvania, United States
🇺🇸Family Practice Medical Associates South, Upper Saint Clair, Pennsylvania, United States
A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT00498212
- Locations
- 🇨🇦
SMBD - Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦White Hills Medical Clinic, St Johns, Newfoundland and Labrador, Canada